Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in ...
Ipsen announced final CABINET Phase III trial data showing Cabometyx® (cabozantinib) significantly reduced disease progression or death risk in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs) versus placebo, presented at ESMO 2024 and published in NEJM. Ipsen has submitted an extension of indication Marketing Authorization to the European Medicines Agency.
Reference News
Ipsen announced final CABINET Phase III trial data showing Cabometyx® (cabozantinib) significantly reduced disease progression or death risk in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs) versus placebo, presented at ESMO 2024 and published in NEJM. Ipsen has submitted an extension of indication Marketing Authorization to the European Medicines Agency.